Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation

Blood Adv. 2022 Mar 8;6(5):1619-1622. doi: 10.1182/bloodadvances.2021004829.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Leukemia, Myeloid, Acute* / therapy
  • Transplantation, Homologous